Gilead Sciences, Inc

Founded in 1987, MedImmune is a pharmaceutical health care company that develops medications for the treatment of cancer, inflammatory diseases and pediatric infections. The company markets products under the trade names of Synagis, Ethyol, FluMist and CytoGam. With more than 3,000 employees, it has operations in the United States, the United Kingdom and the Netherlands. MedImmune offers a selection of clinical testing products for the detection of cardiovascular and gastrointestinal diseases. The company provides the HUMIRA brand of medicine for the treatment of crohn's disease, ankylosing spondylitis rheumatoid, chronic plaque psoriasis and juvenile rheumatoid arthritis. In addition, it assists with the development of investigational human monoclonal antibodies for targeting interferon alpha in patients with systemic lupus erythematosus.

Emergent BioSolutions is a biopharmaceutical company headquartered in Rockville, Md. It develops, manufactures and commercializes a range of immunobiotics, including vaccines and therapeutics. Its BioThrax vaccine, approved by the Food and Drug Administration, is used for the prevention of anthrax infection. The company s commercial business focuses on immunobiotics that are used against infectious diseases and other medical conditions. Its commercial portfolio includes vaccines for hepatitis, meningitis and typhoid disorders. Emergent BioSolutions operates various offices in Singapore, Germany and the United Kingdom. It also maintains a network of third-party marketing representatives in the Middle East, Turkey, India, Australia and several Scandinavian countries in Europe.

AstraZeneca is a leading biopharmaceutical company committed to pushing the boundaries of science to provide life-changing medicines for patients worldwide. With a focus on oncology, the organization aims to transform healthcare by addressing significant health challenges and striving for breakthroughs in patient care. The company prioritizes innovation through its research and development efforts, particularly in the fields of cancer treatment, and significantly invests in improving healthcare accessibility. AstraZeneca's ambition is to mitigate the impacts of degenerative and life-threatening conditions through targeted therapies and supportive services. Generated from the website